AdipoR2 agonist possibly reduces colonic fibrosis in UC and fistulae in CD by restoring balance of TIMP1 and TGFB1. High-level APN is not necessarily beneficial, and the dose-effect relationship between APN and IBD is not simply dose-dependent. This evidence concerns the gene TIMP1 and inflammatory bowel disease.